Archive for the ‘Oramed Pharmaceuticals Inc. ORMP’ Category

Beacon Equity Research Featured Company: Oramed Pharmaceuticals, Inc. (ORMP.OB)

Tuesday, February 26th, 2008

Oramed Pharmaceuticals, Inc. (ORMP.OB) is a company focused on the commercial development of proprietary oral therapies. Oramed’s main focus is the treatment of diabetes via an oral insulin capsule, which has the potential to help millions of diabetics worldwide. The Company’s oral insulin will better control diabetes by ingesting the capsule at an earlier stage of one’s treatment. Furthermore, based on Oramed’s patented technology, its top scientists are developing other methods of oral delivery for drugs and vaccinations that are currently not available in an oral form.

According to the World Health Organization, the global diabetic population exceeds 177 million patients worldwide. Insulin is administered to these patients through painful daily injections. Oramed Pharmaceuticals’ oral insulin product offers a pain-free alternative for diabetics.

In addition to the oral insulin, Oramed is in the process of registering an Israeli patent for another method of insulin delivery and is beginning pre-clinical testing of an oral replacement for the flu vaccine. Over one billion doses of the flu vaccine are administered in a year.

The Oramed research team consists of scientists with more than 25 years of clinical experience in leading research and development efforts.

Let us hear your thoughts: Oramed Pharmaceuticals, Inc. Message Board

Beacon Equity Research Highlights: Oramed Pharmaceuticals Inc. (ORMP.OB), as the Company Moves Forward with an Investigational New Drug Application

Monday, June 25th, 2007

Beacon Equity Research Rates Oramed Pharmaceuticals, Inc. as “Speculative Buy”. 

Oramed Pharmaceuticals, Inc.(ORMP.OB), recently reported a new business initiative. 

The Israeli company focused on the development of oral delivery solutions based on proprietary technology and Encorium Group, Inc. (Nasdaq: ENCO), an international full service contract research organization (CRO) that provides comprehensive clinical and drug development solutions for pharmaceutical, biotechnology and medical device companies have reached an agreement. 

The agreement is intended to expedite the development of Oramed’s lead product for treatment of diabetes mellitus.

Encorium Group has extensive worldwide experience in the drug/biologics development process for a multitude of agents and disease conditions and specifically in diabetes, including preclinical to post-marketing support studies.

This agreement engages Encorium Group to assist Oramed in the design, implementation, advancement, and oversight of a sound scientific and regulatory strategic plan for the filing and ultimate approval of Oramed’s oral insulin product on a worldwide basis.

The initial focus of this combined effort between Oramed and Encorium Group is to assemble the information required for the opening of an investigational new drug application (IND) and its subsequent filing with the FDA.

Let us hear your thoughts below: